Treatment for obesity

Patent metadata

Field	Value
Publication number	US-12201601-B2
Application number	US-202218055017-A
Country	US
Kind code	B2
Filing date	Nov 14, 2022
Priority date	Jul 18, 2013
Publication date	Jan 21, 2025
Grant date	Jan 21, 2025

Abstract

The present invention relates to a method for treating or preventing obesity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. The invention further relates to methods for reducing body weight and/or reducing food intake in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.

First claim

We claim:

1. A method for treating pathological eating in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):

or a pharmaceutically acceptable salt or ester thereof;
wherein R is a member selected from the group consisting of alkyl of 1 to 8 carbon atoms, halogen, alkoxy of 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy of 1 to 3 carbon atoms;
x is 0;
R 1 and R 2 are hydrogen;
thereby treating the pathological eating.

2. A method for reducing or preventing body weight gain in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):

or a pharmaceutically acceptable salt or ester thereof;
wherein R is a member selected from the group consisting of alkyl of 1 to 8 carbon atoms, halogen, alkoxy of 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy of 1 to 3 carbon atoms;
x is 0;
R 1 and R2 are hydrogen;
wherein the subject reduces body weight or prevents body weight gain.

3. A method for decreasing food consumption in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):

or a pharmaceutically acceptable salt or ester thereof;
wherein R is a member selected from the group consisting of alkyl of 1 to 8 carbon atoms, halogen, alkoxy of 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy of 1 to 3 carbon atoms;
x is 0;
R 1 and R 2 are hydrogen;
wherein the subject reduces food intake.

4. The method of claim 1 , wherein the compound of Formula I is an enantiomer of Formula I substantially free of other enantiomers or an enantiomeric mixture wherein one enantiomer of Formula I predominates.

5. The method of claim 4 , wherein the enantiomer of Formula I substantially free of other enantiomers is the compound of Formula Ib or an enantiomeric mixture wherein the compound of Formula Ib predominates:

or a pharmaceutically acceptable salt or ester thereof.

6. The method of claim 5 , wherein the compound of Formula Ib predominates to the extent of about 98% or greater.

7. The method of claim 1 , wherein the compound of Formula I is administered orally.

8. The method of claim 1 , wherein the compound of Formula I is administered in the form of a capsule or tablet at a dose of about 10 mg to about 1000 mg without any excipients.

9. The method of claim 2 , wherein the compound of Formula I is an enantiomer of Formula I substantially free of other enantiomers or an enantiomeric mixture wherein one enantiomer of Formula I predominates.

10. The method of claim 9 , wherein the enantiomer of Formula I substantially free of other enantiomers is the compound of Formula Ib or an enantiomeric mixture wherein the compound of Formula Ib predominates:

or a pharmaceutically acceptable salt or ester thereof.

11. The method of claim 10 , wherein the compound of Formula Ib predominates to the extent of about 98% or greater.

12. The method of claim 2 , wherein the compound of Formula I is administered orally.

13. The method of claim 2 , wherein the compound of Formula I is administered in the form of a capsule or tablet at a dose of about 10 mg to about 1000 mg without any excipients.

14. The method of claim 3 , wherein the compound of Formula I is an enantiomer of Formula I substantially free of other enantiomers or an enantiomeric mixture wherein one enantiomer of Formula I predominates.

15. The method of claim 14 , wherein the enantiomer of Formula I substantially free of other enantiomers is the compound of Formula Ib or an enantiomeric mixture wherein the compound of Formula Ib predominates:

or a pharmaceutically acceptable salt or ester thereof.

16. The method of claim 15 , wherein the compound of Formula Ib predominates to the extent of about 98% or greater.

17. The method of claim 3 , wherein the compound of Formula I is administered orally.

18. The method of claim 3 , wherein the compound of Formula I is administered in the form of a capsule or tablet at a dose of about 10 mg to about 1000 mg without any excipients.

19. A method for treating obesity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):

or a pharmaceutically acceptable salt or ester thereof;
wherein R is a member selected from the group consisting of alkyl of 1 to 8 carbon atoms, halogen, alkoxy of 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy of 1 to 3 carbon atoms;
x is 0; and
R 1 and R 2 are hydrogen;
thereby treating the obesity.

20. The method of claim 19 , wherein the compound of Formula I is an enantiomer of Formula I substantially free of other enantiomers or an enantiomeric mixture wherein one enantiomer of Formula I predominates.

21. The method of claim 20 , wherein the enantiomer of Formula I substantially free of other enantiomers is the compound of Formula Ib or an enantiomeric mixture wherein the compound of Formula Ib predominates:

or a pharmaceutically acceptable salt or ester thereof.

22. The method of claim 21 , wherein the compound of Formula Ib predominates to the extent of about 98% or greater.

23. The method of claim 19 , wherein the compound of Formula I is administered orally.

24. The method of claim 19 , wherein the compound of Formula I is administered in the form of a capsule at a dose of about 10 mg to about 1000 mg without any excipients.

Assignees

• Axsome Malta Ltd
• Sk Biopharmaceuticals Co Ltd

Inventors

• Khayrallah Moise A
• Bream Gary
• Butts Stephen E

Classifications

• A61K9/48

  Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)} · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• A61K31/27 Primary

  of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine · CPC title